May 3, 2010 (FinancialWire) — Akorn, Inc. (NASDAQ: AKRX) said that directors Jerry N. Ellis and Randy J. Wall, have notified the company that they do not intend to seek re-election at the annual meeting of shareholders on May 21, 2010. The company’s board has nominated Kenneth S. Abramowitz as a director.

Abramowitz is a co-founder and managing general partner of NGN Capital. He joined NGN from The Carlyle Group in New York, where he was managing director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry.

Prior to that, Abramowitz worked as an analyst at Sanford C. Bernstein & Co., where he covered the medical supply, hospital management and HMO industries for 23 years.

According to Akorn, Ellis and Wall will continue to serve as directors until the May 21 meeting.

Illinois-based Akorn is engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey where the company manufactures ophthalmic and injectable pharmaceuticals.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [rgltryrtl] [cmplncz] [gvrncnr]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.